Acentric Research is produced with AI tools under human review. It is affiliated with Acentric Capital, a private investment group whose members may hold positions in companies discussed. The authors are not financial professionals, and nothing here is investment advice or a recommendation to buy or sell any security. AI analysis can be wrong; check every claim against its cited source.
This Brief is an initial scan, not a full investigation. The method and scores behind it are in AI × Biotechnology in the Landscape Report.
Overview
Many medical devices now contain software that has learned, from large sets of examples, to read an image or a stream of sensor data and report what it sees: a possible skin cancer, a sign of diabetic eye disease, the likelihood of a heart attack. This Brief covers that area: artificial intelligence (AI) inside devices that help find disease. In FDA’s example of a skin-cancer imaging system, the algorithms give the diagnostic information.
What stands out is that this area already has many marketed products. The U.S. Food and Drug Administration (FDA) states that it has authorized over 1,600 AI-enabled medical devices for marketing in the United States as of September 2026. [1] That number covers AI-enabled devices of all kinds, not only diagnostic and imaging ones. It lists devices authorized for marketing; it does not show how well they work for patients, and company financing for the area was not examined. The one dated source besides FDA’s list, a company prospectus, is from August 2025; later developments were not searched.
Current state
What the devices do. FDA describes AI-enabled medical devices as able to analyze large and complex datasets, identify patterns and generate information that may support disease detection, diagnosis and treatment. [1] Its own examples include an imaging system that uses algorithms to give diagnostic information for skin cancer, software that uses deep learning to sharpen images, AI systems that can detect diabetic retinopathy from retinal images, and a smart sensor that estimates the probability of a heart attack. [1] The list also includes devices outside diagnosis, such as algorithms that automate insulin dosing from continuous glucose monitor readings. [1]
How far it has come. These devices are authorized for marketing in the United States. FDA says it reviews medical devices through an appropriate premarket pathway, such as premarket clearance (510(k)), De Novo classification or premarket approval, and that a marketing submission may include one or more AI-enabled software functions. [1] FDA states that it does not regulate AI as such; it regulates medical devices, including software. [1]
One company, in its own words. Many companies make such devices; Heartflow is described here as one example because it filed a public prospectus with the U.S. Securities and Exchange Commission (SEC) in August 2025. It says it has “pioneered the use of software and AI to deliver a more accurate and clinically effective non-invasive solution for diagnosing and managing coronary artery disease”. Its platform, it says, combines AI and computational fluid dynamics to create a personalized 3D model of a patient’s heart from a single coronary computed tomography angiography scan, a specialized scan of the heart’s arteries. [2] The company describes the disease as a leading cause of death worldwide and says healthcare systems generally lack scalable methods to detect, diagnose and quantify it at a personalized level. These are the company’s statements, as of its 2025 filing. [2]
Rules for the software. FDA notes that some AI-enabled devices may adapt over time as new data, information or experience becomes available, which raises questions about how a device is monitored after authorization. [1] FDA lists a final guidance on predetermined change control plans for AI-enabled device software functions. A change control plan lets a manufacturer describe in advance how its software may change after authorization. FDA also lists a draft guidance on lifecycle management and marketing submissions for AI-enabled device software, a set of good machine learning practice principles, and advisory committee meetings on generative AI in devices in 2024 and 2025. [1]
Opportunities
The rules for software that changes after authorization are still being settled. A final change control plan guidance already exists, and the lifecycle guidance is still a draft; how FDA settles it will affect how manufacturers update their software. [1] FDA describes the potential of AI-enabled devices to support earlier disease detection and diagnosis, personalized diagnostics and improved device usability. [1] FDA also lists a discussion paper on measuring and evaluating the performance of AI-enabled devices in the real world. [1]
Challenges
- Regulation. FDA reviews devices through an appropriate premarket pathway, and FDA notes that AI-enabled devices raise considerations that extend across the product life cycle, from development and validation through deployment, monitoring and modification. [1]
- Evidence of benefit. FDA’s list covers devices authorized for marketing. No source opened for this Brief reports patient outcomes for these devices.
- Capital and scale-up. Company financing for this area was not searched. Heartflow’s prospectus is one company’s own account and is not a measure of the area as a whole. [2]
Data sources
- FDA’s list of AI-enabled devices, a searchable resource that FDA updates periodically. [1]
- FDA’s 510(k), De Novo and premarket approval (PMA) databases, for each device’s submission record. [3] No source opened gives a count limited to diagnostic and imaging devices.
- SEC EDGAR, for company prospectuses and annual reports, where companies describe their products and sales in their own words. [4]
- ClinicalTrials.gov, for studies that test these devices in patients. [5] No good source for post-market performance was opened.
Changelog
- 2026-11-18: First published.
Sources
- US Food and Drug Administration, “Artificial Intelligence-Enabled Medical Devices”. fda.gov (accessed 2026-11-18)
- Heartflow, Inc., prospectus (Form 424B4), filed 2025-08-08 (company statements). sec.gov (accessed 2026-11-18)
- US Food and Drug Administration, “Medical Device Databases”. fda.gov (accessed 2026-11-18)
- US Securities and Exchange Commission, “Search Filings” (EDGAR). sec.gov (accessed 2026-11-18)
- National Library of Medicine, ClinicalTrials.gov. clinicaltrials.gov (accessed 2026-11-18)